Читать книгу Interventional Cardiology - Группа авторов - Страница 300

Acetylsalicylic acid irreversibly inactivates the cyclooxygenase enzyme exerting antiplatelet as well as anti‐inflammatory actions. In view of its efficacy, low cost, and widespread availability, all NSTE‐ACS patients should receive it, unless they have a contraindication [33]. Both the American and European guidelines give a class I recommendation for early aspirin administration in patients with NSTE‐ACS. Proposed dosing is 81–325 mg (325 mg for all patients if not already on aspirin prior to PCI) for the United States and 150–300 mg (or 80–150 mg I.V.) for Europe [13,14]. After the acute phase, life‐long treatment is recommended.